BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26028398)

  • 81. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015.
    Wang X; Cao Y; Wu Y; Yang C; Song J; Tian Y; Wang M; Li M; Wu Y; Hu Y
    Medicine (Baltimore); 2019 Feb; 98(8):e14370. PubMed ID: 30813137
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Insight into antidiabetic therapies: a report from the 43rd annual meeting of the European Association for the Study of Diabetes.
    Rabasseda X
    Timely Top Med Cardiovasc Dis; 2007 Oct; 11():E28. PubMed ID: 18297140
    [No Abstract]   [Full Text] [Related]  

  • 84. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
    He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
    J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.
    Tanabe M; Nomiyama T; Motonaga R; Murase K; Yanase T
    BMC Endocr Disord; 2015 Sep; 15():49. PubMed ID: 26382923
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Glucose-lowering medicines for type 2 diabetes.
    Davoren P
    Aust Fam Physician; 2015 May; 44(5):176-9. PubMed ID: 26042396
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Oral agents in the management of type 2 diabetes mellitus.
    Luna B; Feinglos MN
    Am Fam Physician; 2001 May; 63(9):1747-56. PubMed ID: 11352285
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Use of oral glucose-lowering agents in patients with renal impairment].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Long-term studies of treatments for type 2 diabetes.
    Caballero AE
    Postgrad Med; 2017 Apr; 129(3):352-365. PubMed ID: 27882816
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Diabetes: Pharmacotherapy for Type 2 Diabetes.
    St Onge E
    FP Essent; 2021 May; 504():22-27. PubMed ID: 33970588
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Diabetes mellitus. Medication update.
    Slagle M
    South Med J; 2002 Jan; 95(1):50-5. PubMed ID: 11827245
    [No Abstract]   [Full Text] [Related]  

  • 94. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.
    Guillausseau PJ
    Curr Diab Rep; 2011 Dec; 11(6):461-2; author reply 463. PubMed ID: 21915770
    [No Abstract]   [Full Text] [Related]  

  • 95. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Fitchett DH; Udell JA; Inzucchi SE
    Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
    Cefalu WT; Buse JB; Del Prato S; Home PD; LeRoith D; Nauck MA; Raz I; Rosenstock J; Riddle MC
    Diabetes Care; 2014 Sep; 37(9):2647-59. PubMed ID: 25147257
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes.
    Yen FS; Cheng-Chung Wei J; Liu JS; Hsu CC; Hwu CM
    Diabetes Res Clin Pract; 2021 Jul; 177():108928. PubMed ID: 34171441
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Seeking sweet relief for diabetes.
    Dove A
    Nat Biotechnol; 2002 Oct; 20(10):977-81. PubMed ID: 12355109
    [No Abstract]   [Full Text] [Related]  

  • 99. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
    Munir KM; Davis SN
    Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close.
    Koufakis T; Mustafa OG; Zebekakis P; Kotsa K
    Diabet Med; 2020 Sep; 37(9):1418-1426. PubMed ID: 32445407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.